MedTrace Logo

Evaluation of Clinical Ranges of Whole Blood Clotting Times of Patients on Anticoagulants

NCT06582563 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2024-10-08

No results posted yet for this study

Summary

Whole blood clotting time measurements are to collect the clotting time ranges for DOAC-anticoagulated patients and assess their correlation with plasma drug levels (via anti-FXa assay).

Conditions

  • Blood Coagulation Disorder

Interventions

DIAGNOSTIC_TEST

Whole Blood Clotting Time

Comparator

Sponsors & Collaborators

  • Perosphere Technologies Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-07-30
Completion
2025-08-30
FDA Device
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06582563 on ClinicalTrials.gov